PubMed
Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin
Winbanks CE, Wang B, Beyer C, et al. American Journal of Physiology — Endocrinology and Metabolism. 2009
Compare
Follistatin 344 vs Retatrutide
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
Follistatin 344
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 100% · Mixed 0% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
6
Sleep
6
Energy
3
Self-reported dose per injection
Median bucket: 50–100 mcg · Most common: 50–100 mcg
Reports span 50–200 mcg
50–100
4
100–200
2
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Retatrutide
125 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 99% · Mixed 1% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
222
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
3
Self-reported dose per injection
Median bucket: 2–3 mg · Most common: 1–2 mg
Reports span 0 to ≥ 5 mg (open-ended top bucket)
0–0.01 mg
5
0.1–0.2 mg
3
0.2–0.4 mg
6
0.4–0.6 mg
10
0.6–1 mg
5
1–2 mg
80
2–3 mg
35
3–5 mg
17
5+ mg
61
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 100% said they felt similar to their last entry, 0% more positive, and 0% more negative.
Overall, repeat reporters leaned similar or mixed compared to their previous entry.
Median gap between entries: 51 days · Based on 45 repeat reporters
Sources (11)
Published sources linked on the Follistatin 344 and Retatrutide wiki pages.
- Wiki study page →Source
- Wiki study page →Source
ClinicalTrials.gov
Follistatin / Myostatin inhibition studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Follistatin-derived peptide expression in muscle decreases adipose tissue mass and prevents hepatic steatosis
Sugiyama M, Yamaki A, Furuya M, et al. American Journal of Physiology — Endocrinology and Metabolism. 2010
- Wiki study page →Source
PubMed
Evaluation of follistatin as a therapeutic in models of skeletal muscle atrophy associated with denervation and tenotomy
Sepulveda PV, Bush ED, Bhattacharya A, et al. Scientific Reports. 2015
- Wiki study page →Source
PubMed
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation
Stefanakis K, Kokkorakis M, Mantzoros CS. Metabolism: clinical and experimental. 2024
- Wiki study page →Source
PubMed
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes
Rosenstock J, Frias J, Jastreboff AM, et al. Lancet. 2023
- Wiki study page →Source
PubMed
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frias JP, et al. N Engl J Med. 2023
- Wiki study page →Source
ClinicalTrials.gov
Retatrutide obesity studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
ClinicalTrials.gov
Retatrutide studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frías JP, et al. The New England journal of medicine. 2023
- Wiki study page →Source
PubMed
Retatrutide-A Game Changer in Obesity Pharmacotherapy
Katsi V, Koutsopoulos G, Fragoulis C, et al. Biomolecules. 2025